Literature DB >> 8977631

Regulation of S100P expression by androgen.

L Averboukh1, P Liang, P W Kantoff, A B Pardee.   

Abstract

BACKGROUND: The growth and function the normal prostate is dependent on the presence of androgen. As prostate tumors progress there is a loss of androgen-dependent cell growth. The identification of the genes that are regulated by androgens may be of pathological and clinical significance.
METHODS: In this study the differential display method was used to identify genes regulated by androgen in an androgen-responsive prostate cancer cell line, LNCaP-FGC.
RESULTS: A gene whose expression is down-regulated in LNCaP-FGC cells after 30 hr of androgen deprivation has been identified. This gene is a previously identified member of the S100 gene family of calcium-binding proteins, namely S100P. Here we show that S100P expression is regulated by the synthetic androgen R1881, but not by serum growth factors. It is dysregulated in the androgen-independent prostate cancer cell lines LNCaP-R, DU145, and PC3.
CONCLUSIONS: The data indicate that S100P may play a role in the etiology of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977631     DOI: 10.1002/(SICI)1097-0045(199612)29:6<350::AID-PROS2>3.0.CO;2-C

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  17 in total

1.  Conformational and thermodynamic properties of peptide binding to the human S100P protein.

Authors:  Alexey V Gribenko; Mercedes Guzmán-Casado; Maria M Lopez; George I Makhatadze
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

2.  NMR structure of the Apo-S100P protein.

Authors:  Yi-Chien Lee; David E Volk; Varatharasa Thiviyanathan; Quinn Kleerekoper; Alexey V Gribenko; Shanmin Zhang; David G Gorenstein; George I Makhatadze; Bruce A Luxon
Journal:  J Biomol NMR       Date:  2004-07       Impact factor: 2.835

3.  Heterodimeric interaction and interfaces of S100A1 and S100P.

Authors:  Guozheng Wang; Shu Zhang; David G Fernig; David Spiller; Marisa Martin-Fernandez; Hongmei Zhang; Yi Ding; Zihe Rao; Philip S Rudland; Roger Barraclough
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

Review 4.  S100P: a novel therapeutic target for cancer.

Authors:  Thiruvengadam Arumugam; Craig D Logsdon
Journal:  Amino Acids       Date:  2010-05-28       Impact factor: 3.520

5.  Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.

Authors:  Thiruvengadam Arumugam; Vijaya Ramachandran; Craig D Logsdon
Journal:  J Natl Cancer Inst       Date:  2006-12-20       Impact factor: 13.506

Review 6.  Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.

Authors:  Hongfei Jiang; Hang Hu; Xiaomei Tong; Qiuhong Jiang; Haiyan Zhu; Songying Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

7.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers.

Authors:  Xiaofei Chang; Constance L Monitto; Semra Demokan; Myoung Sook Kim; Steven S Chang; Xiaoli Zhong; Joseph A Califano; David Sidransky
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

8.  Overexpression of S100P promotes colorectal cancer metastasis and decreases chemosensitivity to 5-FU in vitro.

Authors:  Lei Dong; Fule Wang; Xiaona Yin; Ling Chen; Gang Li; Feiyan Lin; Wuhua Ni; Jianbo Wu; Rong Jin; Lei Jiang
Journal:  Mol Cell Biochem       Date:  2014-01-01       Impact factor: 3.396

9.  Molecular analysis and characterization of PrEC, commercially available prostate epithelial cells.

Authors:  Richard E Sobel; Yuzhuo Wang; Marianne D Sadar
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jan-Feb       Impact factor: 2.416

10.  Characterization of the tissue-specific expression of the s100P gene which encodes an EF-hand Ca2+-binding protein.

Authors:  Gang Jin; Shu Wang; Xiangui Hu; Zaiping Jing; Jinzhong Chen; Kang Ying; Yi Xie; Yumin Mao
Journal:  Mol Biol Rep       Date:  2003-12       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.